Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Development of treatments for canine parvovirus

EF 2018-19

Résumé
Amongst infectious diseases, canine parvovirus is one of the leading causes of morbidity and mortality in dogs.*Infection results in fever, vomiting, dehydration, and diarrhea. Untreated, most dogs will die from the infection.*Current therapies rely on high-cost supportive therapies, such as blood transfusions, IV feeding, and 24-hour*care at veterinary hospitals. Canine parvovirus infections are very costly to dog owners, which includes a third*of Canadian households. NovoBind Livestock Therapeutics Inc. proposes to develop novel antibody-based*strategies that could be provided to dog owners to prevent canine parvovirus infections or be available to*veterinarians as a therapeutic to be administered to infected dogs. Currently, novel canine parvovirus-specific*antibodies (NBXs) are being generated by NovoBind. This proposal relies on the expertise of Dr. Nelly Panté*and her laboratory in the fields of parvovirus biology and cell biology. The work described here will provide*proof-of-concept that NovoBind's strategy can block canine parvovirus infectivity and will enable NovoBind's*eventual selection of the best antibodies against canine parvovirus. The development of prophylactic and*therapeutic products targeting canine parvovirus would benefit all dog owners as they will provide faster and*more economical options for dealing with canine parvovirus. The revenue generated by NovoBind in delivering*this product would also be an economic boost to Canada as would the recovery of lost productivity that occurs*when dog owners must forgo work to care for their dogs.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
526581-2018
Name nom
Panté, Nelly
Department département
Zoology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Partie
1
Nb partie
1
Application title
Development of treatments for canine parvovirus
Keyword
NSERC
Application summary
Amongst infectious diseases, canine parvovirus is one of the leading causes of morbidity and mortality in dogs.*Infection results in fever, vomiting, dehydration, and diarrhea. Untreated, most dogs will die from the infection.*Current therapies rely on high-cost supportive therapies, such as blood transfusions, IV feeding, and 24-hour*care at veterinary hospitals. Canine parvovirus infections are very costly to dog owners, which includes a third*of Canadian households. NovoBind Livestock Therapeutics Inc. proposes to develop novel antibody-based*strategies that could be provided to dog owners to prevent canine parvovirus infections or be available to*veterinarians as a therapeutic to be administered to infected dogs. Currently, novel canine parvovirus-specific*antibodies (NBXs) are being generated by NovoBind. This proposal relies on the expertise of Dr. Nelly Panté*and her laboratory in the fields of parvovirus biology and cell biology. The work described here will provide*proof-of-concept that NovoBind's strategy can block canine parvovirus infectivity and will enable NovoBind's*eventual selection of the best antibodies against canine parvovirus. The development of prophylactic and*therapeutic products targeting canine parvovirus would benefit all dog owners as they will provide faster and*more economical options for dealing with canine parvovirus. The revenue generated by NovoBind in delivering*this product would also be an economic boost to Canada as would the recovery of lost productivity that occurs*when dog owners must forgo work to care for their dogs.